# Role of LSD1 in Hypertension and Renal Injury in Blacks

> **NIH NIH K23** · BRIGHAM AND WOMEN'S HOSPITAL · 2022 · $192,632

## Abstract

PROJECT SUMMARY/ABSTRACT
This translational research proposal focuses on lysine-specific demethylase 1 (LSD1), an epigenetic regulator
of gene transcription. The project’s overall aim is to show that polymorphisms in LSD1 (rs587168) are involved
in blood pressure regulation and the pathophysiology of renal injury in Blacks, and that excess mineralocorticoid
receptor activity mediates these effects. The applicant will address this hypothesis using a database approach
(Aim 1) and a physiology-directed study in Black hypertensives (Aim 2). Specific Aim 1 will determine whether
Black LSD1 risk allele carriers have greater evidence of renal damage (albuminuria) than non-risk allele carriers.
The applicant will perform a cross-sectional study in 180 hypertensive Blacks (90 risk and 90 non-risk LSD1
allele carriers) from the International Hypertension Pathotype Cohort (HyperPATH) to assess whether urine
albumin/creatinine levels (marker of renal glomerular and tubular damage) and Kidney Injury Molecule-1 (marker
of renal tubular damage) are higher in Black LSD1 risk allele carriers vs non-risk allele carriers. Specific Aim 2
is a proof-of-principle physiologic study in hypertensive Black LSD1 risk allele carriers testing the hypothesis that
reductions in blood pressure will be greater with a genetically-driven anti-hypertensive approach
(mineralocorticoid receptor antagonist, eplerenone) compared to a non-specific approach (amlodipine). 56
participants will be enrolled in a 12-week randomized, double-blind, active controlled, outpatient study to assess
whether eplerenone (LSD1 specific treatment) proves superior in 24-hr ambulatory systolic blood pressure
reduction than amlodipine (non-specific treatment). If Aim1 is positive, the applicant will also assess change in
urine albumin and KIM-1 levels in the longitudinal study. Successful completion of these Aims will document
whether a genetic marker, LSD1, identifies Black individuals whose blood pressure is uniquely responsive to
mineralocorticoid receptor blockade--personalized, precision medicine. Further, results of this project have the
potential to reduce Black-White disparities in health outcomes secondary to poor blood pressure control.
The training plan includes dedicated mentorship by Gordon Williams, MD (Mentor) and Gail Adler, MD, PhD (co-
Mentor), international experts in the field of cardiovascular endocrinology. In addition to Drs. Williams and Adler,
the applicant will have an advisory team composed of Bernard Rosner, PhD (statistician), Joseph Bonventre,
MD, PhD (nephrologist), and Herman Taylor, MD (cardiologist), each offering expertise tailored to the applicant’s
needs and goals. Also, the applicant will complete formal training in clinical/translational investigation, clinical
trial design, and statistics at the Harvard T.H. Chan School of Public Health. These activities will provide the
applicant with the necessary tools critical for development toward her goal of becoming an indepen...

## Key facts

- **NIH application ID:** 10478286
- **Project number:** 5K23HL155076-02
- **Recipient organization:** BRIGHAM AND WOMEN'S HOSPITAL
- **Principal Investigator:** Andrea Haas
- **Activity code:** K23 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $192,632
- **Award type:** 5
- **Project period:** 2021-09-01 → 2026-09-14

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10478286

## Citation

> US National Institutes of Health, RePORTER application 10478286, Role of LSD1 in Hypertension and Renal Injury in Blacks (5K23HL155076-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10478286. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*